Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

By F. Hodi, W. Hwu, R. Kefford, J. Weber, A. Daud, O. Hamid, A. Patnaik, Antoni Ribas, C. Robert, T. Gangadhar and 11 more. Journal of Clinical Oncology, 2016

661 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/487da99b64441d9bd9faf119e280366c1491f7bb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Turtle
2. K. Hay
3. L. Hanafi
4. Daniel H. Li
5. S. Cherian
6. S. Riddell
7. Xueyan Chen
8. B. Wood

Citations in the corpus

• Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (2018, neutral): “Median age, years (IQR) 33 (26-45) 37 (28-48) 32 (25-47) 34 (26-46) $ 60 5 (8) 7 (9) 3 (3) 15 (6) Male 34 (54) 51 (64) 56 (56) 141 (58) ECOG PS 0 39 (62) 42 (53) 50 (50) 131 (54) 1 24 (38) 38 (48) 50 (50) 112 (46) Disease stage at study entry I 1 (2) 1 (1) 2 (2) 4 (2) II 20 (32) 11 (14) 20 (20) 51 (”
• Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 (2016, background): “Interestingly, these new immunotherapies also result in novel tumor response patterns such as delayed tumor responses or pseudoprogressions (8, 9).”
• Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. (2017, background): “These data indicate that early restaging by tumor size criteria alone, 4 weeks after CAR-T cell administration, may not be the optimal determinant of prognosis, as suggested after immune checkpoint blockade in other malignancies.(24,25) Additional studies will be required to determine whether strate”
• A systematic review and network meta‐analysis of immunotherapy and targeted therapy for advanced melanoma (2017, background): “Appraising the PFS and RR scenarios, it was conceivable that BRAFi- MEKi would dominate them, as BRAFMEK inhibition was already known to produce frequent and rapid responses, whereas immunotherapy may take longer to produce sustained tumor shrinkage and even lead to unconventional response patterns ”